BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25423691)

  • 1. The role of levonorgestrel-releasing intrauterine system for endometrial protection in women with breast cancer taking tamoxifen.
    Shi Q; Li J; Li M; Wu J; Yao Q; Xing A
    Eur J Gynaecol Oncol; 2014; 35(5):492-8. PubMed ID: 25423691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Romero SA; Young K; Hickey M; Su HI
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD007245. PubMed ID: 33348436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Dominick S; Hickey M; Chin J; Su HI
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007245. PubMed ID: 26649916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Chin J; Konje JC; Hickey M
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis.
    Fu Y; Zhuang Z
    Int J Clin Exp Pathol; 2014; 7(10):6419-29. PubMed ID: 25400720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral and intrauterine progestogens for atypical endometrial hyperplasia.
    Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD009458. PubMed ID: 30521671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review.
    Wan YL; Holland C
    Climacteric; 2011 Dec; 14(6):622-32. PubMed ID: 22017273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women.
    Chan SS; Tam WH; Yeo W; Yu MM; Ng DP; Wong AW; Kwan WH; Yuen PM
    BJOG; 2007 Dec; 114(12):1510-5. PubMed ID: 17995495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial.
    Gardner FJ; Konje JC; Bell SC; Abrams KR; Brown LJ; Taylor DJ; Habiba M
    Gynecol Oncol; 2009 Sep; 114(3):452-6. PubMed ID: 19576623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
    Lethaby A; Hussain M; Rishworth JR; Rees MC
    Cochrane Database Syst Rev; 2015 Apr; (4):CD002126. PubMed ID: 25924648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The levonorgestrel-releasing intrauterine device induces endometrial decidualisation in women on tamoxifen.
    Philip S; Taylor AH; Konje JC; Habiba M
    J Obstet Gynaecol; 2019 Nov; 39(8):1117-1122. PubMed ID: 31195902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
    Lethaby AE; Cooke I; Rees M
    Cochrane Database Syst Rev; 2005 Oct; (4):CD002126. PubMed ID: 16235297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial.
    Wong AWY; Chan SSC; Yeo W; Yu MY; Tam WH
    Obstet Gynecol; 2013 May; 121(5):943-950. PubMed ID: 23635729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia.
    Ewies AA; Alfhaily F
    Obstet Gynecol Surv; 2012 Nov; 67(11):726-33. PubMed ID: 23151756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia.
    Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
    Cochrane Database Syst Rev; 2013 Jun; (6):CD009458. PubMed ID: 23737032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levonorgestrel intrauterine system in adjuvant tamoxifen treatment: balance of breast risks and endometrial benefits--systematic review of literature.
    Gizzo S; Di Gangi S; Bertocco A; Noventa M; Fagherazzi S; Ancona E; Saccardi C; Patrelli TS; D'Antona D; Nardelli GB
    Reprod Sci; 2014 Apr; 21(4):423-31. PubMed ID: 24060633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial.
    Gardner FJ; Konje JC; Abrams KR; Brown LJ; Khanna S; Al-Azzawi F; Bell SC; Taylor DJ
    Lancet; 2000 Nov; 356(9243):1711-7. PubMed ID: 11095258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
    Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK
    Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women.
    Morelli M; Di Cello A; Venturella R; Mocciaro R; D'Alessandro P; Zullo F
    Gynecol Endocrinol; 2013 Feb; 29(2):156-9. PubMed ID: 23134558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.